What did @healthwithnyrah actually say?
The creator, identified as a pharmacist, described Wegovy as containing "semagluetide" (semaglutide), said it's typically prescribed to patients with a BMI over 30, and compared it to something called "Sixth Sender" while saying it mimics a hormone that reduces appetite and calorie intake. They acknowledged FDA approval and clinical trial testing, then added a general warning that "all weight loss medication comes with side effects." The video closes with an open question to the audience rather than a concrete takeaway. That framing, asking what viewers think about a medication, is a curious choice for someone with a pharmacist credential and nearly 900,000 viewers watching.
The core framework here is not wrong. Semaglutide does mimic a gut hormone, it does reduce appetite, and Wegovy is FDA approved. But the details matter a lot with a drug this widely discussed, and some of the details here are noticeably off.
Does the science back this up?
The hormone-mimicking mechanism is accurate, and the clinical evidence behind semaglutide is genuinely strong. The science does support the broad strokes of what the creator said, but the specifics are fuzzy enough to matter.
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone released naturally after eating. It stimulates insulin secretion, slows gastric emptying, and signals satiety to the brain. Semaglutide mimics this hormone with a longer half-life, meaning it stays active for about a week, which is why Wegovy is a once-weekly injection.
The pivotal trial for Wegovy was the STEP 1 study (Wilding et al., 2021, New England Journal of Medicine), which found that adults with obesity who took 2.4mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% in the placebo group. That is a meaningful clinical result. A subsequent cardiovascular outcomes trial, SELECT (Lincoff et al., 2023, NEJM), showed a 20% reduction in major cardiovascular events in people with obesity and established cardiovascular disease. The evidence base is not thin. The creator's vague reference to "some clinical trials" undersells it considerably.
What did they get wrong (or right)?
There are two clear errors here and one right answer buried in imprecise language. The errors deserve naming directly.
First, "Sixth Sender" is not a drug. It is not a brand name, a generic, or a category. It does not exist in any pharmacological classification. The creator almost certainly meant Saxenda, which is liraglutide, another GLP-1 receptor agonist made by Novo Nordisk. Saxenda and Wegovy are both GLP-1 agonists, but they are different drugs with different molecules, different dosing schedules, and different clinical trial results. Liraglutide is a daily injection; semaglutide is weekly. The SELECT cardiovascular data applies to semaglutide, not liraglutide. Conflating them, especially under a garbled name, is a real error for a pharmacist-identified creator.
Second, the BMI threshold is incomplete. Wegovy's FDA-approved indication is a BMI of 30 or greater, OR a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. Saying it is "usually given to patients with a BMI of over 30" cuts out a meaningful patient population.
What they got right: semaglutide does mimic a naturally occurring hormone, it does reduce appetite, and yes, side effects exist and matter. That part is accurate.
What should you actually know?
If you are considering Wegovy or any semaglutide product, the drug's mechanism and approval status are just the starting point. The side effect profile is real and worth understanding before you start.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. In the STEP trials, around 44% of participants on semaglutide reported nausea. Most cases were mild to moderate and decreased over time, but they are a real reason some people discontinue the medication. There are also rarer but more serious risks, including a potential association with pancreatitis and, in animal studies (not confirmed in humans), thyroid C-cell tumors. Wegovy carries a boxed warning about this risk, which the creator did not mention.
Muscle mass loss is another underreported concern. A study by Malhotra et al. (2024, Journal of the American College of Cardiology) noted that a significant portion of weight lost on GLP-1 drugs can be lean mass, not just fat. Resistance training and adequate protein intake are increasingly recommended alongside these medications.
Finally, weight typically returns after stopping the drug. This is not a short-term fix. The STEP 4 trial (Rubino et al., 2021, JAMA) showed participants regained two-thirds of their lost weight within a year of discontinuation.
Bottom line
The creator gets the broad mechanism right but delivers it with an unidentified drug name, an incomplete prescribing threshold, and a clinical trial record described as "some." For a pharmacist-identified account with nearly a million views, the accuracy bar should be higher than this. The science behind semaglutide is actually compelling enough to speak plainly about. Vague is not the same as safe.